Gilead’s $4.3B Bet on CymaBay’s Liver Drug
Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
- Latest
- Trending
Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
Morgan Stanley reiterates its Overweight rating on ASICS Corp, with a target price of JPY6,400. The positive outlook is driven ...
Toronto-based ecommerce brand portfolio, Emerge Commerce, sees surge in shares after achieving positive organic revenue growth in January. Investor confidence ...
Shares of TOP Financial Group Ltd. tumbled 12.2% in premarket trading today after a surge on Friday. The stock's volatility ...
Shares of Tod's SpA surged 17% after a delisting plan and takeover bid by L Catterton, valuing the luxury goods ...
Pegasystems is expected to announce strong fourth-quarter results, supported by stable spending and ongoing digital transformation initiatives. Analysts believe in ...
MGM Resorts is expected to announce strong Q4 earnings with a 15.1% YoY increase in revenue. Analysts are optimistic about ...
Toy and entertainment company Hasbro is expected to face a challenging quarter with a decline in revenue and adjusted earnings. ...
Denny's is expected to report a decline in Q4 revenue, raising concerns among investors. Analysts have revised estimates downward, but ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.